“Stable Clear-Almost Clear Response Is Sustained up to 3 Years in Patients With Moderate-To-Severe Atopic Dermatitis Treated With Lebrikizumab”. SKIN The Journal of Cutaneous Medicine 9, no. 6 (November 10, 2025): s599. Accessed April 25, 2026. https://skin.dermsquared.com/skin/article/view/3832.